Primary endpoints of phase III trials for older patients with cancer

被引：1
|
作者：
Mizutani, T. [1 ]
机构：
[1] Kyorin Univ, Fac Med, Dept Med Oncol, Mitaka, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1702P
引用
收藏
页码：S1187 / S1187
页数：1
相关论文
共 50 条
  • [21] Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study
    Tack, Laura
    Lefebvre, Tessa
    Lycke, Michelle
    Pottel, Lies
    Cool, Lieselot
    Ketelaars, Lore
    De Zutter, Jolien
    Martens, Evi
    Pottel, Hans
    Stellamans, Karin
    Van Eygen, Koen
    Werbrouck, Patrick
    Vergauwe, Philippe
    Wildiers, Hans
    Schofield, Patricia
    Boterberg, Tom
    Debruyne, Philip R.
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (02) : 320 - 326
  • [22] Phase III randomized trials of docetaxel in patients with metastatic breast cancer
    Crown, J
    SEMINARS IN ONCOLOGY, 1999, 26 (03) : 33 - 38
  • [23] Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
    Fausto Petrelli
    Sandro Barni
    Medical Oncology, 2014, 31
  • [24] Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials
    Petrelli, Fausto
    Barni, Sandro
    MEDICAL ONCOLOGY, 2014, 31 (01)
  • [25] A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic breast cancer clinical trials
    Tatla, Raman
    Landaverde, Denis
    Victor, Charles
    Miles, David
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [26] A review of clinical endpoints and use of quality of life outcomes in phase III metastatic breast cancer clinical trials.
    Tatla, Raman
    Landaverde, Denis
    Victor, Charles
    Miles, David
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Primary endpoints for irritable bowel syndrome trials: A review of performance of endpoints
    Camilleri, Michael
    Mangel, Allen W.
    Fehnel, Sheri E.
    Drossman, Douglas A.
    Mayer, Emeran A.
    Talley, Nicholas J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (05) : 534 - 540
  • [28] Re: Underrepresentation of Vulnerable Older Patients with Cancer in Phase II and III Oncology Registration Trials: A Case-Control Study
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2020, 203 (05): : 859 - 860
  • [29] Physicians' Perception of the Evidence in Relation to Primary Endpoints of Clinical Trials on Breast Cancer
    Zhang, Yi
    Liu, Miao
    Yang, Houpu
    Wang, Shu
    BREAST CARE, 2022, 17 (02) : 180 - 187
  • [30] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC).
    Kuemmel, Sherko
    Mueller, Volkmar
    Lux, Michael P.
    Weyer, Geerd
    Pintoffl, Jan P.
    Jackisch, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345